中國集成控股(01027.HK)2019年度虧損約1600萬元
格隆匯3月31日丨中國集成控股(01027.HK)發佈全年業績,2019年度,收益增加約7.3%至約人民幣5.59億元;毛利減少約16.5%至約人民幣6600萬元;年內虧損約人民幣1600萬元(2018年:年內溢利約人民幣1900萬元);每股基本虧損約人民幣0.43分;董事不建議派發末期股息。
公告表示,集團財務表現大幅下滑主要是由於貿易的威脅,令毛利減少;銷售及分銷開支(包括為支持集團業務擴張及爭取市場份額的市場營銷及推廣開支)增加;就2019年度收購一間附屬公司而應收或然代價公平值變動產生虧損約人民幣750萬元;及就2019年度授出購股權的一次過非現金購股權開支約人民幣670萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.